{
    "clinical_study": {
        "@rank": "109352", 
        "arm_group": {
            "arm_group_label": "interferon", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell\n      transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.\n\n      Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients.\n\n      the study is to evaluate the safety and efficacy of interferon for the intervention of\n      molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell\n      transplantation (allo-SCT)"
        }, 
        "brief_title": "Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  high risk t (8; 21) AML\n\n          -  molecular relapse after allo-SCT\n\n        Exclusion Criteria:\n\n          -  active graft-versus-host disease\n\n          -  uncontrolled severe infection\n\n          -  organ function failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027064", 
            "org_study_id": "PUPH IRB [2013](38)"
        }, 
        "intervention": {
            "arm_group_label": "interferon", 
            "intervention_name": "Interferon-alpha", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "ywyw3172@sina.com", 
                "last_name": "yu wang, M.D.", 
                "phone": "861088326666", 
                "phone_ext": "4952"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100044"
                }, 
                "name": "Peking University People's Hospital"
            }, 
            "investigator": {
                "last_name": "xiao-jun huang, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "ywyw3172@sina.com", 
            "last_name": "yu wang, M.D.", 
            "phone": "861088326666", 
            "phone_ext": "4952"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "number of participants with morphologic relapse at one year", 
            "measure": "relapse rate", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed for an expected average of 365 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027064"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University People's Hospital", 
            "investigator_full_name": "Xiaojun Huang", 
            "investigator_title": "director of Peking University People's Hospital, institute of hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}